In vitro models of TGF-β-induced fibrosis suitable for high-throughput screening of antifibrotic agents
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Progressive fibrosis is a cause of progressive organ dysfunction. Lack of quantitative in vitro models of fibrosis accounts, at least partially, for the slow progress in developing effective antifibrotic drugs. Here, we report two complementary in vitro models of fibrosis suitable for high-throughput screening. We found that, in mesangial cells and renal fibroblasts grown in eight-well chamber slides, transforming growth factor-β1 (TGF-β1) disrupted the cell monolayer and induced cell migration into nodules in a dose-, time- and Smad3-dependent manner. The nodules contained increased interstitial collagens and showed an increased collagen I:IV ratio. Nodules are likely a biological consequence of TGF-β1-induced matrix overexpression since they were mimicked by addition of collagen I to the cell culture medium. TGF-β1-induced nodule formation was inhibited by vacuum ionized gas treatment of the plate surface. This blockage was further enhanced by precoating plates with matrix proteins but was prevented, at least in part, by poly-l-lysine (PLL). We have established two cell-based models of TGF-β-induced fibrogenesis, using mesangial cells or fibroblasts cultured in matrix protein or PLL-coated 96-well plates, on which TGF-β1-induced two-dimensional matrix accumulation, three-dimensional nodule formation, and monolayer disruption can be quantitated either spectrophotometrically or by using a colony counter, respectively. As a proof of principle, chemical inhibitors of Alk5 and the antifibrotic compound tranilast were shown to have inhibitory activities in both assays.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765
Human renal mesangial cells are a target for the anti-inflammatory action of 9-cis retinoic acid
Manzano, V. M., Muñoz, J. C. S., Jiménez, J. R., Puyol, M. R., Puyol, D. R., Kitamura, M., & Cazaña, F. J. L. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703728 · Cited by 35 · cited 1×
“Human mesangial cells (HMCs) were obtained from adult kidney tissue, as we have previously described, and were used between passages 8 and 12 (28).”
Method
Cited by
Organ printing: Tissue spheroids as building blocks
Mironov, V., Visconti, R. P., Kasyanov, V., Forgacs, G., Drake, C. J., & Markwald, R. R. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2008.12.084 · Cited by 1,238
Targeting metabolic dysregulation for fibrosis therapy
Zhao, X., Kwan, J. Y. Y., Yip, K., Liu, P. P., & Liu, F.-F. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0040-5 · Cited by 513
Prud'homme, G. J. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700669 · Cited by 419
Mias, C., Lairez, O., Trouche, E., Roncalli, J., Calise, D., Seguelas, M.-H., Ordener, C., Piercecchi-Marti, M.-D., Auge, N., Salvayre, A. N., et al. (2009) · Stem Cells · doi:10.1002/stem.169 · Cited by 280
Role of the lesion scar in the response to damage and repair of the central nervous system
Kawano, H., Kimura-Kuroda, J., Komuta, Y., Yoshioka, N., Li, H. P., Kawamura, K., Li, Y., & Raisman, G. (2012) · Cell and Tissue Research · doi:10.1007/s00441-012-1336-5 · Cited by 273
Metadata
- Authors
- Xu, Q., Norman, J. T., Shrivastav, S., Lucio-Cazana, J., & Kopp, J. B.
- Venue
- American Journal of Physiology-Renal Physiology
- Publisher
- American Physiological Society
- Published
- 2007-08
- Volume
- 293
- Issue
- 2
- Pages
- F631-F640
- ISSN
- 1522-1466 (ISSN-L)
- 1931-857X
- OpenAlex
- W2145010183
- Cited by
- 130
- References
- 2
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.